Literature DB >> 1559048

AIDS and the transition to illicit drug injection--results of a randomized trial prevention program.

D C Des Jarlais1, C Casriel, S R Friedman, A Rosenblum.   

Abstract

Illicit drug injection is a major component of the AIDS epidemic in the United States, Europe and some developing countries. Prevention of illicit drug injection would not only reduce HIV transmission but would also reduce the other health, psychological and social problems associated with illicit drug injection. One hundred and four subjects who were using heroin intranasally ('sniffing') were recruited for a study of the transition to drug injection. Eligibility criteria included sniffing as the most frequent route of administration and no more than 60 injections in the past 2 years. All subjects received thorough basic information about AIDS, including HIV antibody test counseling. Subjects were then randomly assigned to a four-session social learning based AIDS/drug injection prevention program or a control condition. Eighty-three subjects were successfully followed at a mean time of 8.9 months. Twenty (24%) of the followed subjects reported injecting illicit drugs during the follow-up period. Drug injection during follow-up was associated with being in the control group, intensity of non-injected drug use, prior injection, and having close personal relationships with current intravenous (IV) drug users.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1559048     DOI: 10.1111/j.1360-0443.1992.tb01950.x

Source DB:  PubMed          Journal:  Br J Addict        ISSN: 0952-0481


  39 in total

1.  Large decline in injecting drug use in Amsterdam, 1986-1998: explanatory mechanisms and determinants of injecting transitions.

Authors:  E J van Ameijden; R A Coutinho
Journal:  J Epidemiol Community Health       Date:  2001-05       Impact factor: 3.710

Review 2.  The social course of drug injection and sexual activity among YMSM and other high-risk youth: an agenda for future research.

Authors:  Michael C Clatts; Lloyd Goldsamt; Alan Neaigus; Dorinda L Welle
Journal:  J Urban Health       Date:  2003-12       Impact factor: 3.671

Review 3.  Updating the infection risk reduction hierarchy: preventing transition into injection.

Authors:  David Vlahov; Crystal M Fuller; Danielle C Ompad; Sandro Galea; Don C Des Jarlais
Journal:  J Urban Health       Date:  2004-03       Impact factor: 3.671

4.  Cessation of injecting drug use among street-based youth.

Authors:  Colin Steensma; Jean-François Boivin; Lucie Blais; Elise Roy
Journal:  J Urban Health       Date:  2005-09-29       Impact factor: 3.671

5.  Potential risk factors for injecting among Mexican American non-injecting heroin users.

Authors:  Avelardo Valdez; Alan Neaigus; Alice Cepeda
Journal:  J Ethn Subst Abuse       Date:  2007       Impact factor: 1.507

6.  The Influence of Family and Peer Risk Networks on Drug Use Practices and Other Risks among Mexican American Noninjecting Heroin Users.

Authors:  Avelardo Valdez; Alan Neaigus; Charles D Kaplan
Journal:  J Contemp Ethnogr       Date:  2008-02-01

7.  Characterizing and improving HIV and hepatitis knowledge among primary prescription opioid abusers.

Authors:  Kelly E Dunn; Kathryn A Saulsgiver; Mollie E Patrick; Sarah H Heil; Stephen T Higgins; Stacey C Sigmon
Journal:  Drug Alcohol Depend       Date:  2013-08-30       Impact factor: 4.492

8.  Drug use generations and patterns of injection drug use: Birth cohort differences among people who inject drugs in Los Angeles and San Francisco, California.

Authors:  Ricky N Bluthenthal; Lynn Wenger; Daniel Chu; Philippe Bourgois; Alex H Kral
Journal:  Drug Alcohol Depend       Date:  2017-04-19       Impact factor: 4.492

9.  Prevalence and correlates of former injection drug use among young noninjecting heroin users in Chicago.

Authors:  Dita Broz; Lawrence J Ouellet
Journal:  Subst Use Misuse       Date:  2010-10       Impact factor: 2.164

10.  Crack cocaine use and its relationship with violence and HIV.

Authors:  Heraclito Barbosa de Carvalho; Sergio Dario Seibel
Journal:  Clinics (Sao Paulo)       Date:  2009       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.